Lee Johnson Capital Management LLC Makes New $2.60 Million Investment in Medtronic PLC $MDT

Lee Johnson Capital Management LLC purchased a new stake in Medtronic PLC (NYSE:MDT) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 27,303 shares of the medical technology company’s stock, valued at approximately $2,600,000.

A number of other hedge funds have also added to or reduced their stakes in the company. 1248 Management LLC acquired a new stake in shares of Medtronic during the first quarter valued at about $26,000. Delos Wealth Advisors LLC acquired a new position in Medtronic in the 2nd quarter valued at approximately $27,000. Twin Tree Management LP bought a new position in shares of Medtronic during the first quarter valued at $29,000. Tripletail Wealth Management LLC bought a new stake in shares of Medtronic in the third quarter worth $34,000. Finally, GFG Capital LLC bought a new stake in shares of Medtronic in the second quarter worth $36,000. 82.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on MDT shares. Robert W. Baird set a $103.00 target price on Medtronic in a research report on Tuesday, December 16th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research report on Monday. Truist Financial reduced their target price on Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a report on Thursday, December 18th. Barclays raised their price target on shares of Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a report on Thursday, November 20th. Finally, Royal Bank Of Canada boosted their price target on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $109.94.

Medtronic Trading Up 0.5%

Shares of MDT stock opened at $96.68 on Wednesday. The company has a market cap of $123.94 billion, a P/E ratio of 26.06, a PEG ratio of 2.53 and a beta of 0.71. Medtronic PLC has a fifty-two week low of $79.38 and a fifty-two week high of $106.33. The stock has a 50 day simple moving average of $97.56 and a two-hundred day simple moving average of $93.92. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. Medtronic’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be issued a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).